文献速递神经肿瘤

帕博利珠单抗单药治疗MSI-H/dMMR复发性胶质瘤:KEYNOTE-158多队列研究结果

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.
PubMed 文献 · J Neurooncol · 2026-04-01

KEYNOTE-158 2期多队列研究聚焦K队列21例MSI-H/dMMR复发性胶质瘤成人患者,接受帕博利珠单抗200 mg每3周一次、最多35周期。中位随访50.0个月,客观缓解率(ORR)为5%(95%CI 0.1%–24%),1例部分缓解、3例疾病稳定,治疗相关不良事件发生率33%(3–4级5%)。

要点

  • MSI-H/dMMR复发性胶质瘤中帕博利珠单抗单药ORR仅5%,获益限于小部分患者
  • 1例部分缓解者PFS 29.2个月、OS 32.7个月,3例疾病稳定者PFS 3.3–23.2个月
  • 治疗相关不良事件33%,3–4级仅5%,安全性总体可控

核心结论

  • 帕博利珠单抗单药在MSI-H/dMMR复发性胶质瘤的小部分患者中显示抗肿瘤活性,安全性可控。

研究设计与样本

  • 2期多队列KEYNOTE-158研究(NCT02628067)中K队列分析,入组≥18岁、MSI-H/dMMR且按RECIST v1.1有可测量病灶的复发性胶质瘤患者。
  • 共纳入21例,接受帕博利珠单抗200 mg每3周一次、最多35周期,主要终点为独立中心影像评审按RECIST v1.1评估的ORR。

主要发现

  • 中位(范围)随访50.0(15.4–65.5)个月,最佳总体疗效为部分缓解1例(5%)、疾病稳定3例(14%)、疾病进展16例(76%),1例(5%)无基线后评估。
  • ORR(95%CI)为5%(0.1%–24%);4例疾病稳定或更好者的缓解持续时间中位(范围)27.8(0.0+–27.8)个月。
  • 部分缓解者PFS 29.2个月、OS 32.7个月;3例疾病稳定者PFS 3.3–23.2个月、OS 9.1–23.2个月。
  • 治疗相关不良事件发生于7/21例(33%),3–4级1例(5%)。

临床怎么用

  • 对MSI-H/dMMR复发性胶质瘤可考虑帕博利珠单抗单药,但需告知ORR仅5%、获益限于小部分患者。
  • 治疗期间按RECIST v1.1影像评估疗效,并监测治疗相关不良事件。

局限性

  • 样本量小(21例),仅为KEYNOTE-158中K队列的亚组分析。
  • 单臂设计,无对照,ORR置信区间宽(0.1%–24%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recurrent gliomas have limited treatment options and dismal outcomes. We report the efficacy and safety of the anti–programmed cell death protein-1 antibody pembrolizumab in participants with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) recurrent glioma in KEYNOTE-158. METHODS: The phase 2, multicohort KEYNOTE-158 study (NCT02628067) is evaluating pembrolizumab monotherapy in participants with advanced rare cancers. This analysis focused on participants with recurrent glioma from cohort K where eligible participants were ≥18 years old with MSI-H/dMMR tumors and measurable disease per RECIST v1.1. Participants received pembrolizumab 200 mg every 3 weeks for up to 35 cycles. The primary endpoint was objective response rate (ORR) per RECIST v1.1 by independent central radiologic review. RESULTS: Twenty-one participants with recurrent glioma were enrolled. Median (range) follow-up was 50.0 (15.4‒65.5) months. Best overall responses were partial response (PR; n = 1, 5%), stable disease (SD; n = 3, 14%), and disease progression (n = 16, 76%); 1 participant (5%) had no postbaseline assessment. ORR (95% CI) was 5% (0.1%‒24%). Of 4 participants with SD or better, median (range) duration of their response was 27.8 (0.0+‒27.8) months. The participant with PR had progression-free survival (PFS) of 29.2 months and overall survival (OS) of 32.7 months; among the 3 participants with SD, PFS ranged from 3.3–23.2 months and OS ranged from 9.1–23.2 months. Treatment-related AEs occurred in 7/21 participants (33%; grade 3‒4, n = 1 [5%]). CONCLUSION: Pembrolizumab monotherapy demonstrated antitumor activity in a small subset of participants and manageable safety in MSI-H/dMMR recurrent glioma. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02628067; Registered, December 9, 2015.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Baldini C, Cassier PA, Delord JP, et al. Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study. J Neurooncol. 2026. PMID: 41920388. doi:10.1007/s11060-026-05461-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。